Quetiapine: here's the fair price
This is what US pharmacies pay, on average, for quetiapine. Use it to spot a fair cash price, and feel good about asking for one.
Quetiapine Fumarate 25 Mg Tab
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Quetiapine Fumarate 25 Mg Tab. Pharmacies pay about $0.63 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| QUETIAPINE FUMARATE 25 MG TABGeneric | $0.02 per tablet or capsule | $0.63 | 10/21/2026 |
| QUETIAPINE FUMARATE 50 MG TABGeneric | $0.03 per tablet or capsule | $0.88 | 10/21/2026 |
| QUETIAPINE FUMARATE 100 MG TABGeneric | $0.05 per tablet or capsule | $1.45 | 10/21/2026 |
| QUETIAPINE FUMARATE 200 MG TABGeneric | $0.09 per tablet or capsule | $2.81 | 10/21/2026 |
| QUETIAPINE ER 50 MG TABLETGeneric | $0.12 per tablet or capsule | $3.72 | 10/21/2026 |
| QUETIAPINE FUMARATE 300 MG TABGeneric | $0.13 per tablet or capsule | $3.83 | 10/21/2026 |
| QUETIAPINE FUMARATE 400 MG TABGeneric | $0.16 per tablet or capsule | $4.80 | 10/21/2026 |
| QUETIAPINE ER 150 MG TABLETGeneric | $0.19 per tablet or capsule | $5.56 | 10/21/2026 |
| QUETIAPINE ER 200 MG TABLETGeneric | $0.22 per tablet or capsule | $6.54 | 10/21/2026 |
| QUETIAPINE ER 300 MG TABLETGeneric | $0.26 per tablet or capsule | $7.67 | 10/21/2026 |
| QUETIAPINE ER 400 MG TABLETGeneric | $0.32 per tablet or capsule | $9.51 | 10/21/2026 |
| QUETIAPINE 150 MG TABLETGeneric | $1.26 per tablet or capsule | $37.66 | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
1 INDICATIONS AND USAGE Quetiapine extended-release tablets are an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1) Bipolar I disorder, manic or mixed episodes (1.2) Bipolar disorder, depressive episodes (1.2) Major depressive disorder, adjunctive therapy with antidepressants (1.3) 1.1 Schizophrenia Quetiapine extended-release tablets are indicated for the treatment of schizophrenia. The efficacy of quetiapine extended-release tablets in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. Efficacy was supported by three 6-week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia...
Common side effects (FDA label)
6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Increased mortality in elderly patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] Suicidal thoughts and behaviors in adolescents and young adults [see Warnings and Precautions (5.2) ] Cerebrovascular adverse reactions, including stroke in elderly patients with dementia-related psychosis [see Warnings and Precautions (5.3) ] Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions (5.4) ] Metabolic changes (hyperglycemia, dyslipidemia, weight...
Drug interactions (from the label)
7 DRUG INTERACTIONS • Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) ( 2.5 , 7.1 , 12.3 ) • Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e.g., phenytoin, rifampin, St. John’s wort) ( 2.6 , 7.1 , 12.3 ) • Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers ( 2.6 , 7.1 , 12.3 ) 7.1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release...
Warnings (from the label)
5 WARNINGS AND PRECAUTIONS • Cerebrovascular Adverse Reactions: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs (5.3) • Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring (5.4) • Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain (5.5) • Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness....
Source: FDA drug label via openFDA, label effective 2025-11-21. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.